US equities |
NVDA $237.22 ▲+1.40% MU $1,057.61 ▼-1.61% SPCX $164.25 ▲+3.33% MSFT $530.72 ▲+2.55% INTC $117.16 ▼-1.82% TSLA $371.91 ▲+0.36% AMD $629.31 ▼-0.73% SNDK $1,725.45 ▲+0.32%
FinancialContent

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

10.42 +0.14 (+1.36%)
Delayed Quote Updated: 9:46 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline to Lead in Securities Fraud Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Deadline to Lead in Securities Fraud Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
NEW YORK, NY - April 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX)... 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
From SkyMedia, LLC
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
Via Finterra
Topics Economy World Trade
News headline image
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026
NEW YORK, NY - April 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX)... 
Via TheNewswire.com
Topics Lawsuit
News headline image
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
From ImmunityBio, Inc.
Via Business Wire
News headline image
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
From Kirby McInerney LLP    
Via Business Wire
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026
NEW YORK, NY - April 8, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX)... 
Via TheNewswire.com
Topics Lawsuit
News headline image
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Why ImmunityBio Stock Slumped on Monday ↗
The FDA isn't happy about how the biotech wanted to promote its cancer drug. 
Via The Motley Fool
News headline image
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >